Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS
Conditions: Rheumatoid Arthritis; Polyarticular Juvenile Idiopathic Arthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Crohn Disease; Ulcerative Colitis; Plaque Psoriasis; Pediatric Plaque Psoriasis; Pediatric Crohns Disease; Hidradenitis Suppurativa; Non-inf ectious Uveitis Intervention: Drug: 40 mg MSB11022 Sponsors: Fresenius Kabi SwissBioSim GmbH; PRA Health Sciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials